series-a
Stage
1
Investors
About
Algeta ASA develops targeted radiopharmaceutical therapies for cancer treatment, specializing in its lead compound Alpharadin for treating bone metastases.
Explore Algeta ASA's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.